{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/12899"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/12899","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"INDUCTION OF NEUROTROPHIC AND DIFFERENTIATION GENES IN NEURAL STEM CELLS BY VALPROIC ACID","abstract":"<p>Valproic acid (<em>2-propylpentanoicacid</em>) has long been in use as an anticonvulsant and mood-stabilizer. Recently, VPA has been shown to inhibit the activity of histone deacetylases (HDACs), resulting in chromatin remodelling and changes in gene expression<em>.</em> Although the molecular mechanism for VPA action in the central nervous is not well understood, many signalling pathways have been suggested as targets for this HDAC inhibitor. For instance, VPA was found to induce differentiation in adult hippocampal neural progenitor cells via the β-catenin-Ras-ERK pathway. Also, VPA up regulated Bcl-2, a neurotrophic/neuroprotective protein, with association of extracellular signal-regulated kinase (ERK-1) and phosphatidylinositol 3- kinase (PI3) pathway activation. In this study, C17.2 neural stem cells were used to examine the effects of VPA on the expression of several neurotrophic factors including; cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF), glial cell-derived neurotrophic factor (GDNF), <em>brain-derived neurotrophic factor</em><em> (</em>BDNF). Other genes including; the orphan nuclear receptor-related factor1 (Nurr-1), the early growth response protein 1(Egr-1), and the sex determining region Y-box-2 (Sox-2) were examined. Histone H3 acetylation and the ERK1/2 pathway were examined as possible targets for VPA action. Treatment with clinically relevant concentrations of VPA (1mM, and 3 mM) induced a significant increase of CDNF protein concentrations. Also, increases in the mRNA expression of GDNF, Nurr-1, and Egr-1 were detected following 24 hours VPA treatment at clinically relevant concentrations. Moreover, an increase of histone H3 acetylation was noticed in C17.2 NSCs. These findings might support the role of VPA in neuronal differentiation and neuroprotection.</p>","abstract_html":"&lt;p&gt;Valproic acid (&lt;em&gt;2-propylpentanoicacid&lt;/em&gt;) has long been in use as an anticonvulsant and mood-stabilizer. Recently, VPA has been shown to inhibit the activity of histone deacetylases (HDACs), resulting in chromatin remodelling and changes in gene expression&lt;em&gt;.&lt;/em&gt; Although the molecular mechanism for VPA action in the central nervous is not well understood, many signalling pathways have been suggested as targets for this HDAC inhibitor. For instance, VPA was found to induce differentiation in adult hippocampal neural progenitor cells via the β-catenin-Ras-ERK pathway. Also, VPA up regulated Bcl-2, a neurotrophic/neuroprotective protein, with association of extracellular signal-regulated kinase (ERK-1) and phosphatidylinositol 3- kinase (PI3) pathway activation. In this study, C17.2 neural stem cells were used to examine the effects of VPA on the expression of several neurotrophic factors including; cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF), glial cell-derived neurotrophic factor (GDNF), &lt;em&gt;brain-derived neurotrophic factor&lt;/em&gt;&lt;em&gt; (&lt;/em&gt;BDNF). Other genes including; the orphan nuclear receptor-related factor1 (Nurr-1), the early growth response protein 1(Egr-1), and the sex determining region Y-box-2 (Sox-2) were examined. Histone H3 acetylation and the ERK1/2 pathway were examined as possible targets for VPA action. Treatment with clinically relevant concentrations of VPA (1mM, and 3 mM) induced a significant increase of CDNF protein concentrations. Also, increases in the mRNA expression of GDNF, Nurr-1, and Egr-1 were detected following 24 hours VPA treatment at clinically relevant concentrations. Moreover, an increase of histone H3 acetylation was noticed in C17.2 NSCs. These findings might support the role of VPA in neuronal differentiation and neuroprotection.&lt;/p&gt;","abstract_has_math":false,"creators":["Almutawaa, Saeed Walaa"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences (Division of Physiology/Pharmacology)","school":null,"contributors":[],"advisors":["Niles, L.P.","Dr. Lobb and Dr. Werstiuk"],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-04","date_published":"2013-04","updated_at":"2026-11-18T19:30:59Z","subjects":["Neural Stem Cells","Valproic acid","neuronal differentiation","neuroprotection","Neurotrophins","Histone acetylation","gene expression","Medical Cell Biology","Medical Molecular Biology","Medical Neurobiology","Medical Pharmacology","Medical Sciences","Medicine and Health Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/8819"],"render_values":[{"text":"https://doi.org/10.71548/8819","href":"https://doi.org/10.71548/8819","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/7746","8805","3988619"],"render_values":[{"text":"opendissertations/7746","href":null,"code":true},{"text":"8805","href":null,"code":true},{"text":"3988619","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/12899","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/12899","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F12899","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Niles, L.P.","Dr. Lobb and Dr. Werstiuk"]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences (Division of Physiology/Pharmacology)"]},{"key":"dc:creator","label":"Author","values":["Almutawaa, Saeed Walaa"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T17:01:07Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-06-18T17:01:07Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-04-03"]},{"key":"dc:date.issued","label":"Date","values":["2013-04"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Neural Stem Cells","Valproic acid","neuronal differentiation","neuroprotection","Neurotrophins","Histone acetylation","gene expression","Medical Cell Biology","Medical Molecular Biology","Medical Neurobiology","Medical Pharmacology","Medical Sciences","Medicine and Health Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/7746","8805","3988619"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/12899","https://doi.org/10.71548/8819"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>Valproic acid (<em>2-propylpentanoicacid</em>) has long been in use as an anticonvulsant and mood-stabilizer. Recently, VPA has been shown to inhibit the activity of histone deacetylases (HDACs), resulting in chromatin remodelling and changes in gene expression<em>.</em> Although the molecular mechanism for VPA action in the central nervous is not well understood, many signalling pathways have been suggested as targets for this HDAC inhibitor. For instance, VPA was found to induce differentiation in adult hippocampal neural progenitor cells via the β-catenin-Ras-ERK pathway. Also, VPA up regulated Bcl-2, a neurotrophic/neuroprotective protein, with association of extracellular signal-regulated kinase (ERK-1) and phosphatidylinositol 3- kinase (PI3) pathway activation. In this study, C17.2 neural stem cells were used to examine the effects of VPA on the expression of several neurotrophic factors including; cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF), glial cell-derived neurotrophic factor (GDNF), <em>brain-derived neurotrophic factor</em><em> (</em>BDNF). Other genes including; the orphan nuclear receptor-related factor1 (Nurr-1), the early growth response protein 1(Egr-1), and the sex determining region Y-box-2 (Sox-2) were examined. Histone H3 acetylation and the ERK1/2 pathway were examined as possible targets for VPA action. Treatment with clinically relevant concentrations of VPA (1mM, and 3 mM) induced a significant increase of CDNF protein concentrations. Also, increases in the mRNA expression of GDNF, Nurr-1, and Egr-1 were detected following 24 hours VPA treatment at clinically relevant concentrations. Moreover, an increase of histone H3 acetylation was noticed in C17.2 NSCs. These findings might support the role of VPA in neuronal differentiation and neuroprotection.</p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["INDUCTION OF NEUROTROPHIC AND DIFFERENTIATION GENES IN NEURAL STEM CELLS BY VALPROIC ACID"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Niles, L.P.","Dr. Lobb and Dr. Werstiuk"],"dc:contributor.department":["Medical Sciences (Division of Physiology/Pharmacology)"],"dc:creator":["Almutawaa, Saeed Walaa"],"dc:date.accessioned":["2014-06-18T17:01:07Z"],"dc:date.available":["2014-06-18T17:01:07Z"],"dc:date.created":["2013-04-03"],"dc:date.issued":["2013-04"],"dc:description.abstract":["<p>Valproic acid (<em>2-propylpentanoicacid</em>) has long been in use as an anticonvulsant and mood-stabilizer. Recently, VPA has been shown to inhibit the activity of histone deacetylases (HDACs), resulting in chromatin remodelling and changes in gene expression<em>.</em> Although the molecular mechanism for VPA action in the central nervous is not well understood, many signalling pathways have been suggested as targets for this HDAC inhibitor. For instance, VPA was found to induce differentiation in adult hippocampal neural progenitor cells via the β-catenin-Ras-ERK pathway. Also, VPA up regulated Bcl-2, a neurotrophic/neuroprotective protein, with association of extracellular signal-regulated kinase (ERK-1) and phosphatidylinositol 3- kinase (PI3) pathway activation. In this study, C17.2 neural stem cells were used to examine the effects of VPA on the expression of several neurotrophic factors including; cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF), glial cell-derived neurotrophic factor (GDNF), <em>brain-derived neurotrophic factor</em><em> (</em>BDNF). Other genes including; the orphan nuclear receptor-related factor1 (Nurr-1), the early growth response protein 1(Egr-1), and the sex determining region Y-box-2 (Sox-2) were examined. Histone H3 acetylation and the ERK1/2 pathway were examined as possible targets for VPA action. Treatment with clinically relevant concentrations of VPA (1mM, and 3 mM) induced a significant increase of CDNF protein concentrations. Also, increases in the mRNA expression of GDNF, Nurr-1, and Egr-1 were detected following 24 hours VPA treatment at clinically relevant concentrations. Moreover, an increase of histone H3 acetylation was noticed in C17.2 NSCs. These findings might support the role of VPA in neuronal differentiation and neuroprotection.</p>"],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.other":["opendissertations/7746","8805","3988619"],"dc:identifier.uri":["http://hdl.handle.net/11375/12899","https://doi.org/10.71548/8819"],"dc:subject":["Neural Stem Cells","Valproic acid","neuronal differentiation","neuroprotection","Neurotrophins","Histone acetylation","gene expression","Medical Cell Biology","Medical Molecular Biology","Medical Neurobiology","Medical Pharmacology","Medical Sciences","Medicine and Health Sciences"],"dc:title":["INDUCTION OF NEUROTROPHIC AND DIFFERENTIATION GENES IN NEURAL STEM CELLS BY VALPROIC ACID"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:30:59Z"}